MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with N

Nabumetone

Nabumetone 500mg tablets

Use with caution

Stability notes for Nabumetone 500mg tablets

Maximum 28 days in MCA. No stability data available but no theoretical concerns with product.

Provenance

This recommendation is based on Nabumetone 500mg film-coated tablets (Tillomed Laboratries Ltd).

Suppliers (5) of Nabumetone 500mg tablets
Nabumetone 500mg tablets (A A H Pharmaceuticals Ltd)
Nabumetone 500mg tablets (Alliance Healthcare (Distribution) Ltd)
Nabumetone 500mg tablets (Medihealth (Northern) Ltd)
Nabumetone 500mg tablets (Phoenix Healthcare Distribution Ltd)
Nabumetone 500mg tablets (Tillomed Laboratories Ltd)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.